SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Okta, Inc. engages in the provision of an identity management platform for enterprises. It operates through the United States and International geographical segments. The firm's products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Cybersecurity stock Okta is actively discussed following a sector-wide reaction to Anthropics' new Claude Code Security tool, sparking community debate on whether the perceived threat to identity management is overblown or if it presents a buying opportunity, particularly with the recently authorized $1 billion share buyback program.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber is trending following its significant $865 million, 10-year AI data center agreement with Nscale Global, a deal that has ignited bullish calls for major revenue growth and a potential short squeeze. However, some in the community remain frustrated by previous delays in deal announcements and the stock's performance compared to peers in the booming AI infrastructure sector.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending amid concerns surrounding its private credit fund's redemption policy changes and asset sales, sparking broader worries about liquidity across the private credit sector. While some fear potential systemic issues and reputational damage, others highlight management's clarification of accelerated capital returns and the strong underlying performance of its diversified asset base.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound is trending amid growing anticipation of a major bullish reversal, driven by its near-max token supply after recent dilution, upcoming V4 developments and strategic partnerships, alongside whispers of increasing institutional accumulation in the DeFi sector.

Pump.fun

PUMP (Pump.fun) is trending due to heightened activity on its platform, with some users speculating on boosts from Solana's fee-sharing model. Community sentiment is sharply polarized by recent news of a lawsuit, whistleblower allegations, and legal issues involving a former developer, prompting extensive debate on its legitimacy and future prospects.

Veeva Systems, Inc. engages in the provision of industry cloud solutions for the global life sciences industry. Its solutions enable pharmaceutical and other life sciences companies to realize the benefits of modern cloud-based architectures and mobile applications for their most critical business functions, without compromising industry-specific functionality or regulatory compliance. The firm's customer relationship management solutions enable its customers to increase the productivity and compliance of their sales and marketing functions. Its regulated content management and collaboration solutions enable its customers to more efficiently manage regulated, content-centric processes across the enterprise. The company's customer master solution enables customers to more effectively manage complex healthcare provider and healthcare organization data. The company was founded by Mark Armenante, Peter P. Gassner, Doug Ostler, Mitch Wallace and Matthew J. Wallach on January 12, 2007, and is headquartered in Pleasanton, CA.

Veeva Systems Inc - Ordinary Shares - Class A

Veeva Systems is trending as its recent earnings beat and raised guidance are overshadowed by market concerns over Salesforce winning key CRM deals in the competitive life sciences software sector. Investors are debating if the current downturn is an overreaction offering a buying opportunity for a company leveraging AI and a significant share buyback, or a sign of intensifying competitive pressures.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

BROKE CRYPTO is trending as its developer commits to a major pivot from a memecoin to a business focused on AI services, including a deepfake and document verification truth engine, and is pursuing accelerator funding. Despite recent price drops and team departures, the community is actively discussing this strategic shift as a unique 'rebuild' opportunity, encouraging accumulation during the current undervalued state, further bolstered by recent token burns.

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

Savara is trending following the FDA's acceptance of its resubmitted Biologics License Application (BLA) for Molbreevi in autoimmune Pulmonary Alveolar Proteinosis (aPAP) and the granting of Priority Review. The community is actively discussing the drug's potential as the first approved therapy for aPAP, anticipating a significant market opportunity and renewed speculation around a possible acquisition.

Generac Holdings, Inc. engages in the business of designing and manufacturing energy technology solutions. It operates under the Domestic and International segments. The Domestic segment includes the legacy Generac business and the acquisitions that are based in the United States and Canada. The International segment focuses on Generac business' Latin American export operations. The company was founded in 1959 and is headquartered in Waukesha, WI.

Generac Holdings Inc

Generac Holdings is drawing significant attention as widespread power outages from recent severe weather drive robust demand for residential generators, with reports of potential supply shortages. This surge is complemented by strong community discussion around the company's expanding presence in backup power solutions for AI data centers and favorable analyst upgrades, alongside chatter about a proposed tax deduction for home generators.

DocuSign, Inc. engages in the provision of cloud-based electronic signature solutions, which helps companies and individuals securely collect information, automate data workflows, and sign anything. The firm automates manual and paper-based processes allowing users to manage all aspects of documented business transactions including identity management, authentication, digital signature, forms and data collection, collaboration, workflow automation, and storage. Its products include eSignature, CLM, Gen for Salesforce, Document Generation, Standards-Based Signatures, Notary and Web Forms. The company was founded by Thomas H. Gonser and Court Lorenzini in 2003 and is headquartered in San Francisco, CA.

DocuSign Inc

DocuSign is trending due to a polarized community debate over whether AI advancements will disrupt its business or enhance its Intelligent Agreement Management platform, following recent earnings that, despite beating estimates, were met with cautious guidance and analyst downgrades. Amidst a broader software sector downturn, investors are sharply divided between seeing DocuSign as a falling knife vulnerable to AI and competition, or as an undervalued opportunity for long-term growth and potential M&A.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average - Here's Why

Assembly Biosciences (NASDAQ:ASMB) Shares Cross Above 200 Day Moving Average - Time to Sell...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat Ratings reports. One...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Average Rating of "Moderate Buy" from Analysts

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are covering the firm, MarketBeat Ratings reports. One...

Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher - Here's What Happened

Assembly Biosciences (NASDAQ:ASMB) Trading 4% Higher - Here's What Happened...

Ellsworth Advisors LLC Acquires New Holdings in Assembly Biosciences, Inc. $ASMB

Ellsworth Advisors LLC bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) during the third quarter, according to the company in its most recent 13F filing with the...

Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6% - What's Next?

Assembly Biosciences (NASDAQ:ASMB) Stock Price Down 6% - Should You Sell...

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

<ul class="summary-bullets"><li>Gilead will advance the clinical development and commercialization of the programs and Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option.</li><li>H.C. Wainwright believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."</li><li>According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes.</li></ul>Shares of Assembly Biosciences Inc closed up 3% on Monday after Gilead Sciences exercised the option to license the company’s programs for recurrent genital herpes in a move applauded by Wall Street. &nbsp;The programs<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.gilead.com/news/news-details/2025/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes"> include</a> investigational candidates ABI-1179 and ABI-5366. Gilead will advance the clinical development and commercialization of the programs under its ongoing collaboration with Assembly Bio which was inked in 2023 and spans 12 years. Assembly Bio will receive a $35 million payment for Gilead’s exercise of the combined HSV program option and remains eligible for up to $330 million in regulatory and commercial milestones, as well as tiered royalties on net sales.H.C. Wainwright analyst Patrick Trucchio subsequently reiterated a ‘Buy’ rating on Assembly Biosciences (ASMB) with a $50 price target. The analyst believes Gilead's opt-in "significantly de-risks the programs and provides Assembly with a strong financial foundation to execute across its pipeline of next-generation antivirals."<h2 class="st-heading-2">About The Programs</h2>Genital herpes is a common sexually transmitted infection (STI) caused by the herpes simplex virus (HSV), leading to painful blisters and sores around the genitals or anus, though many people have mild or no symptoms and don't know they're infected. Spread through skin-to-skin contact, especially during sex, the virus stays in the body, causing recurring outbreaks triggered by stress, illness, or fatigue.According to Gilead, over four million people in the U.S. and major European countries experience recurrent genital herpes. No new therapies have been approved for HSV in the U.S. or Europe for more than 25 years, the company noted.ABI-1179 and ABI-5366 are novel long-acting inhibitors of viral helicase-primase, an enzyme essential for herpes virus replication. Positive interim Phase 1b data for ABI-5366 and ABI-1179 demonstrated strong antiviral activity and improvements in clinical outcomes, including significant reduction in virus-positive lesions, the company noted. Both compounds also exhibit pharmacokinetic and safety profiles supportive of once-weekly oral dosing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/ASMB"> ASMB </a>rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.Sentiment around GILD stayed within the 'neutral' territory in the meantime.<a href="https://stocktwits.com/symbol/GILD">Shares of GILD</a> have risen nearly 34% this year while ASMB shares have more than doubled.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-rival-ula-ceo-tory-bruno-steps-down/cLeFtcyREub">SpaceX Rival ULA CEO Tory Bruno Steps Down After 12 Years — Says ‘My Work Here Is Now Complete’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Gilead Sciences company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Assembly Biosciences Stock Jumps After Wall Street Says Gilead Opt-In ‘Significantly De-Risks’ Genital Herpes Programs

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.

Equity

Gilead Sciences exercised the option to license Assembly Biosciences’ programs for recurrent genital herpes, including investigational candidates ABI-1179 and ABI-5366.


Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - Should You Buy?

Assembly Biosciences (NASDAQ:ASMB) Sees Strong Trading Volume - What's Next...

Assembly Biosciences' (ASMB) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Monday...

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

ASMB
Assembly Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ASMB News

ASMBAssembly Biosciences Inc